...
首页> 外文期刊>Urological research >Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
【24h】

Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.

机译:纤溶酶原和集落刺激因子-1相关标志物在膀胱癌中的应用:利用免疫细胞化学分析,尿激酶纤溶酶原激活物受体和2型纤溶酶原激活物抑制剂的诊断价值。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The expression of plasminogen- and colony-stimulating factor-1-associated markers was first investigated in seven bladder carcinoma cell lines and in 15 primary bladder tumors using RT-PCR (mRNAs), zymography (protein activity), ELISA and immunocytochemistry analysis (ICC) (protein levels). The mRNAs expression, the activity and the levels of the secreted proteins were not informative. Only urokinase plasminogen activator receptor (uPA-R/CD87) and possibly plasminogen activator inhibitor type-2 (PAI2) antigen expression at the cellular levels seem to be useful markers. uPA-R antigen expression correlated with the secretion of hepatocyte growth factor (HGF) ( P=0.016) and the motility of the bladder tumor cells ( P=0.014), two markers associated with a poor prognosis in bladder carcinoma. To validate our technique and confirm these preliminary results, uPA-R and PAI2 antigen expression was determined in the imprints from 129 resected bladder carcinoma fragments. uPA-R correlated with the grade ( P=0.002), tumor invasion ( P=0.003) and the ploidy ( P=0.05) of the bladder carcinomas and with the low overall survival ( P=0.045) of the patients. PAI2 correlated only with the stage ( P=0.02) and low overall survival ( P=0.038). We conclude that in bladder carcinomas, studying the transcripts of PAs, PAIs, CSF-1 and its receptor, as well as measuring their concentration or activity in culture supernatants was of no clinical interest in terms of diagnostic or prognostic value. Only the ICC of uPA-R, which correlated with the major histopathological parameters of tumors and the low overall survival, proved to be a diagnostic and prognostic marker.
机译:首次使用RT-PCR(mRNA),酶谱(蛋白质活性),ELISA和免疫细胞化学分析(ICC)在7种膀胱癌细胞系和15种原发性膀胱肿瘤中研究了纤溶酶原和集落刺激因子1相关标记的表达)(蛋白质水平)。 mRNA的表达,活性和分泌蛋白的水平均不能提供信息。在细胞水平上,只有尿激酶纤溶酶原激活物受体(uPA-R / CD87)和纤溶酶原激活物抑制剂2型(PAI2)抗原表达似乎是有用的标记。 uPA-R抗原表达与肝细胞生长因子(HGF)的分泌(P = 0.016)和膀胱肿瘤细胞的运动性(P = 0.014)相关,这两个标志物与膀胱癌预后不良相关。为了验证我们的技术并确认这些初步结果,在来自129个切除的膀胱癌片段的印迹中确定了uPA-R和PAI2抗原的表达。 uPA-R与膀胱癌的分级(P = 0.002),肿瘤浸润(P = 0.003)和倍性(P = 0.05)以及患者的总生存率低(P = 0.045)相关。 PAI2仅与阶段(P = 0.02)和总体生存率低(P = 0.038)相关。我们得出的结论是,在膀胱癌中,研究PAs,PAIs,CSF-1及其受体的转录本以及测量其在培养上清液中的浓度或活性对诊断或预后价值均无临床意义。只有uPA-R的ICC与肿瘤的主要组织病理学参数和较低的总生存率相关,才被证明是诊断和预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号